Compare CANF & BTTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANF | BTTC |
|---|---|---|
| Founded | 1994 | 1990 |
| Country | Israel | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.4M |
| IPO Year | 2011 | 2024 |
| Metric | CANF | BTTC |
|---|---|---|
| Price | $1.88 | $0.39 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | 25.6K | ★ 4.9M |
| Earning Date | 09-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.34 |
| 52 Week High | $10.40 | $10.05 |
| Indicator | CANF | BTTC |
|---|---|---|
| Relative Strength Index (RSI) | 32.86 | 42.42 |
| Support Level | N/A | $0.34 |
| Resistance Level | $2.27 | $0.88 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 29.70 | 7.22 |
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Black Titan Corp provides human resource and payroll consulting, software implementation, and training solutions using PeopleSoft platforms. The company's revenue is mainly derived from the provision of HCM solutions, followed by the provision of IT staff augmentation, outsourcing and consulting services.